CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

CSL-Vifor

More Like This

PR Newswire associated0

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

PR Newswire associated0

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

PR Newswire associated0

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

PR Newswire associated0

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

PR Newswire associated0

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy